Emergent BioSolutions Inc.
EBS
Rank in Stocks
#14614
Emergent BioSolutions Inc. is a life sciences company dedicated to providing... Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
Share Price
$6.10
Last synced: 2026-11-09
Market Cap
$312.77M
Change (1 day)
0.66%
Change (1 year)
-43.93%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Emergent BioSolutions Inc. (EBS)
Category
Healthcare
EPS for Emergent BioSolutions Inc. (EBS)
EPS as of September 2026 TTM: $-5.04
According to Emergent BioSolutions Inc.'s latest financial reports, its current EPS (TTM) is $-5.04. At the end of 2025 the company had an EPS of $0.98, an increase over its 2024 EPS of $-3.60.
EPS history for Emergent BioSolutions Inc. from 2001 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-5.04 | -614.29% |
| 2025 | $0.98 | -127.22% |
| 2024 | $-3.60 | -75.76% |
| 2023 | $-14.85 | 251.90% |
| 2022 | $-4.22 | -202.93% |
| 2021 | $4.10 | -29.19% |
| 2020 | $5.79 | 446.23% |
| 2019 | $1.06 | -15.20% |
| 2018 | $1.25 | -36.87% |
| 2017 | $1.98 | 53.49% |
| 2016 | $1.29 | -20.86% |
| 2015 | $1.63 | 66.33% |
| 2014 | $0.98 | 13.95% |
| 2013 | $0.86 | 32.31% |
| 2012 | $0.65 | 0.00% |
| 2011 | $0.65 | -60.12% |
| 2010 | $1.63 | 59.80% |
| 2009 | $1.02 | 47.83% |
| 2008 | $0.69 | -12.66% |
| 2007 | $0.79 | -20.20% |
| 2006 | $0.99 | 28.57% |
| 2005 | $0.77 | 26.23% |
| 2004 | $0.61 | 154.17% |
| 2003 | $0.24 | -87.82% |
| 2002 | $1.97 | -6,666.67% |
| 2001 | $-0.03 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -410.71% |
US
|
|
| $-7.07 | 40.28% |
US
|
|
| $-5.29 | 4.96% |
AU
|
|
| $12.88 | -355.56% |
BE
|
|
| $21.56 | -527.78% |
NL
|
Questions about Emergent BioSolutions Inc.'s earnings per share (EPS)
What is Emergent BioSolutions Inc.'s earnings per share (EPS)?
Emergent BioSolutions Inc.'s earnings per share (EPS) over the last twelve months is $-5.04, as of Sep 2026.
What was Emergent BioSolutions Inc.'s earnings per share (EPS) in 2025?
In 2025, Emergent BioSolutions Inc.'s earnings per share (EPS) was $0.98, compared with $-3.60 in 2024.
How has Emergent BioSolutions Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Emergent BioSolutions Inc.'s earnings per share (EPS) went from $5.79 to $0.98, an average decline of 29.90% a year.
How does Emergent BioSolutions Inc.'s earnings per share (EPS) compare with similar companies?
Emergent BioSolutions Inc.'s earnings per share (EPS) ($-5.04) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.